Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–41.
Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989–1004.
Sampogna F, Tabolli S, Abeni D, et al. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92:299–303.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5.
Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7.
Russo PAJ, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45:155–61.
Lavda AC, Webb TL, Thompson AR. A meta-analysis of the effectiveness of psychological interventions for adults with skin conditions. Br J Dermatol. 2012;167:970–9.
British Association of Dermatologists: National Survey on Psychodermatology services. http://www.bad.org.uk//site/1464/default.aspx. (Accessed May 27, 2013).
Fortune DG, Richards HL, Kirby B, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol. 2003;139:752–6.
Gupta MA, Gupta AK, Kirkby S, Schork NJ. A psychocutaneous profile or psoriasis patients who are stress reactors: a study of 127 patients. Gen Hosp Psychiatry. 1989;11:166–73.
Al’Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol. 1994;130:199–203.
Fortune DG, Richards HL, Main CJ, Griffiths CEM. What patients with psoriasis believe about their condition. J Am Acad Dermatol. 1998;39:196–201.
Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Effect of daily stressors on psoriasis: a prospective study. J Invest Dermatol. 2009;129:2075–7.
Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol. 2009;161:295–9.
Cannon WB. The emergency function of the adrenal medulla in pain and the major emotions. Am J Physiol. 1914;33:356–72.
Qiu BS, Vallance BA, Blennerhassett PA, et al. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med. 1999;5:1178–82.
Cacioppo JT, Berntson GG, Malarkey WB, et al. Autonomic, neuroendocrine, and immune responses to psychological stress: the reactivity hypothesis. Ann N Y Acad Sci. 1998;840:664–73.
Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5:243–51.
Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann NY Acad Sci. 1999;876:1–11.
McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Corticotropin-releasing hormone signalling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1a corticotrophin-releasing hormone receptor. Arthritis Rheum. 2001;44:1761–7.
Ito N, Ito T, Kromminha A, et al. Human hair follicles display a functional equivalent of the hypothalamic–pituitary–adrenal axis and synthesize cortisol. FASEB J. 2005;19:1332–4.
Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19:514–20.
Matsumoto I, Inoue Y, Shimada T, et al. Brain mast cells act as an immune gate to the hypothalamic–pituitary–adrenal axis in dogs. J Exp Med. 2001;194:71–8.
Bethin KE, Vogt SK, Muglia LJ. Interleukin-6 is an essential, corticotrophin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA. 2000;97:9317–22.
Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol. 2004;500:399–411.
Richards HI, Ray DW, Kirby B, et al. Response of the hypothalamic–pituitary–adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol. 2005;153:1114–20.
Bear MF, Connors BW, Paradiso MA. Neuroscience exploring the brain. 2nd ed. Baltimore: Lippincott Williams and Wilkins; 2001.
Dhabhar FS. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann N Y Acad Sci. 2000;917:876–93.
Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–8.
Fortune DG, Richards HL, Main CJ, Griffiths CEM. Pathological worrying, illness perceptions and disease severity in patients with psoriasis. Br J Health Psychol. 2000;5:71–82.
Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32:188–90.
Mizara A, Papadopoulos L, McBride SR. Core beliefs and psychological distress in patients with psoriasis and atopic eczema attending secondary care: the role of schemas in chronic skin disease. Br J Dermatol. 2012;166:986–93.
Sampogna F, Tabolli S, Abeni D. The impact of changes in clinical severity of psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol. 2007;157:508–13.
Choi J, Koo JYM. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49:S57–61.
Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol. 1999;140:887–90.
Fortune DG, Richards HL, Kirby B, et al. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients’ well-being. Br J Dermatol. 2004;151:1219–26.
Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137:755–60.
Wahl A, Moum T, Hanestad BR, Wiklund I. The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis. Qual Life Res. 1999;8:319–26.
Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:267–71.
Vladut CI, Kallay È. Psychosocial implications of psoriasis—theoretical review. Cogn Brain Behav. 2010;14:23–35.
Kleyn CE, McKie S, Ross AR, et al. Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol. 2009;129:2613–9.
Baughman RD, Sobel R. Psoriasis: a measure of severity. Arch Dermatol. 1970;101:390–5.
Zachariae R, Zachariae H, Blomqvis K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146:1006–16.
Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004;151:1227–33.
Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res. 1992;16:143–63.
Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol. 2002;41:157–74.
Richards HL, Fortune DG, Griffiths CE, Main CJ. Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res. 2005;58:89–96.
Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20:53–63.
Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92:67–72.
Ginsburg IH, Link BG. Psychosocial consequence of rejection and stigma feelings in psoriatic patients. Int J Dermatol. 1993;32:587–91.
Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experienced in dermatologic disorders. Cutis. 1998;61:339–42.
Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol. 2007;156:1245–50.
Poot F, Antoine E, Gravellier M, et al. A case-control study on family dysfunction in patients with alopecia areata, psoriasis and atopic dermatitis. Acta Derm Venereol. 2011;91:415–21.
Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259–62.
Sampogna F, Gisondi P, Tabolli S, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Impairment of sexual life in patients with psoriasis. Dermatology. 2007;214:144–50.
Goulding JM, Price CL, Defty CL, Hulangamuwa CS, Bader E, Ahmed I. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol. 2011;154:103–9.
Hughes JE, Barraclough BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br J Psychol. 1983;143:51–4.
Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772–80.
Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57:963–71.
Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatol Treat. 2011;22:337–47.
Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66:e67–76.
Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24–8.
Higgins EM, Peters TJ, du Vivier AW. Smoking, drinking and psoriasis. Br J Dermatol. 1993;129:749–50.
McAleer MA, Mason DL, Cunningham S, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol. 2011;164:1256–61.
Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158:138–40.
Mills CM, Srivastava ED, Harvey IM. Smoking habits in psoriasis: a case controlled study. Br J Dermatol. 1992;127:18–21.
Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol. 1993;28:730–2.
Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135:1490–3.
Naldi L, Parazzini P, Brevi A, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol. 1992;127:212–7.
Naldi L. Cigarette smoking and psoriasis. Clin Dermatol. 1998;16:571–4.
Gordon KB, Langley RG, Lenardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat. 2007;18:25–31.
Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.
Himmerich H, Fulda S, Linseisen J, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry. 2008;23:421–9.
Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994;18(Suppl 1):S147–53.
Illman J, Corringham R, Robinson D Jr, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 2005;3:37–50.
Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29–35.
Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457–65.
Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol. 1998;38:197–200.
D’Erme AM, Zanieri F, Campolmi E, et al. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate–severe psoriasis and psychiatric comorbidity: a retrospective study. J Eur Acad Dermatol Venereol. 2012 (Epub ahead of print).
Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother. 1992;26:211–2.
Tan Pei Lin L, Kwek SK. Onset of psoriasis during therapy with fluoxetine. Gen Hosp Psychiatry. 2010;32:446.e9–10.
Tamer E, Gur G, Polat M, Alli N. Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? J Dermatol Treat. 2009;20:137–40.
Cox NH, Gordon PM, Dodd H. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment. Br J Dermatol. 2002;146:1061–3.
Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010;49:1351–61.
Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60:625–32.
Gaston L, Crombez JC, Joly J, et al. Efficacy of imagery and meditation techniques in treating psoriasis. Imagin Cogn Pers. 1988;8:25–38.
Vedhara K, Morris RM, Booth R, et al. Changes in mood predict disease activity and quality of life in patients with psoriasis following emotional disclosure. J Psychosom Res. 2007;62:611–9.
Paradisi A, Abeni D, Finore E, et al. Effect of written emotional disclosure interventions in persons with psoriasis undergoing narrow band ultraviolet B phototherapy. Eur J Dermatol. 2010;20:599–605.
Papadopoulos L. Psychological therapies for dermatological problems. In: Walker C, Papadopoulos L, editors. Psychodermatology: the psychological impact of skin disorders. Cambridge: Cambridge University Press; 2005. p. 29–43.
Tausk F, Whitmore S. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom. 1999;68:221–5.
Price ML, Mottahedin I, Mayo PR. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol. 1991;16:114–7.
Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610–6.
Wahl A, Hanestad BR, Wiklund I, Moum T. Coping and quality of life in patients with psoriasis. Qual Life Res. 1999;8:427–33.
Scharloo M, Kaptein AA, Weinman J, et al. Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol. 2000;142:899–907.
Fortune DG, Richards HL, Kirby B, et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146:458–65.
Zacharie R, Oster H, Bjerring P, Kragballe K. Effects of psychologic intervention on psoriasis: a preliminary report. J Am Acad Dermatol. 1996;34:1008–15.
National Institute for Clinical Excellence (NICE) clinical guideline 153 (Oct 2012). Psoriasis. The assessment and management of psoriasis. http://www.nice.org.uk/nicemedia/live/13938/61192/61192.pdf. (Accessed June 21, 2013).
Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. http://www.abw-verlag.com/db_picture.php?120;BOOKS_BookList;Leseprobe. (Accessed Oct 28, 2012).
Scottish Intercollegiate Guidelines Network (2010). Diagnosis and management of psoriasis and psoriatic arthritis in adults. Edinburgh: SIGN (SIGN publication no. 121). http://www.sign.ac.uk/guidelines/fulltext/121/contents.html. (Accessed Oct 28, 2012).
Bewley AP, Fleming C, Taylor R. Psychocutaneous medicine and its provision in the UK. Poster presentation at the Annual Meeting of the British Association of Dermatologists, 2012. Abstract number P32 Br J Dermatol. 2012;167(Suppl.1):36.
Department of Health (2011). No Health Without Mental Health: A cross-government mental health outcomes strategy for people of all ages. http://www.dh.gov.uk/health/2011/07/mental-health-strategy. (Accessed June 21, 2013).